Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPFFR1 | Q9GZQ6 | 6/20 | 0.58 |
| ▸ | NPFFR2 | Q9Y5X5 | 6/20 | 0.58 |
| ▸ | DPP4 | P27487 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1031172 | 0.93 | NPFFR1 (0.53) | NPFFR1NPFFR2DPP4CYP2D6ALDH1A1 | |
| SCHEMBL8606869 | 0.86 | NPFFR1 (0.57) | NPFFR1NPFFR2CYP2D6ALDH1A1KMT2A | |
| SCHEMBL22055750 | 0.86 | POLB (0.47) | NPFFR1NPFFR2MCHR1KMT2ASIGMAR1 | |
| SCHEMBL7504889 | 0.86 | CYP2D6 (0.52) | NPFFR1NPFFR2CYP2D6ALDH1A1KMT2A | |
| SCHEMBL23268296 | 0.85 | NPFFR1 (0.56) | NPFFR1NPFFR2CYP2D6ALDH1A1KMT2A | |
| SCHEMBL17606484 | 0.85 | NPFFR1 (0.61) | NPFFR1NPFFR2CYP2D6ALDH1A1KMT2A | |
| SCHEMBL6703813 | 0.85 | NPFFR1 (0.61) | NPFFR1NPFFR2CYP2D6ALDH1A1KMT2A | |
| SCHEMBL7315847 | 0.85 | NPFFR1 (0.56) | NPFFR1NPFFR2DPP4CYP2D6ALDH1A1 | |
| SCHEMBL3958497 | 0.84 | CYP2D6 (0.62) | NPFFR1NPFFR2CYP2D6ALDH1A1KMT2A | |
| SCHEMBL7578999 | 0.84 | NPFFR1 (0.55) | NPFFR1NPFFR2CYP2D6ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11932643-B2 | Substituted heterocyclic inhibitors of PTPN11 | NAVIRE PHARMA, INC. (US) | 2024-03-19 | — | — | US | disclosed |
| US-11840536-B2 | Heterocyclic inhibitors of PTPN11 | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-12-12 | — | — | US | disclosed |
| CN-112351780-B | Substituted heterocyclic inhibitors of PTPN11 | 纳维尔制药有限公司 | 2023-12-01 | — | — | CN | disclosed |
| US-20230109858-A1 | HETEROCYCLIC INHIBITORS OF PTPN11 | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2023-04-13 | — | — | US | disclosed |
| EP-3463343-B1 | HETEROCYCLIC INHIBITORS OF PTPN11 | UNIV TEXAS (US) | 2022-03-23 | — | — | EP | disclosed |
| US-20210317122-A1 | SUBSTITUTED HETEROCYCLIC INHIBITORS OF PTPN11 | Cantero Therapeutics, Inc. | 2021-10-14 | — | — | US | disclosed |
| CN-109475531-B | Heterocyclic inhibitors of PTPN11 | 得克萨斯州立大学董事会 | 2021-08-17 | — | — | CN | disclosed |
| US-10954243-B2 | Substituted heterocyclic inhibitors of PTPN11 | NAVIRE PHARMA, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| EP-3787627-A1 | SUBSTITUTED HETEROCYCLIC INHIBITORS OF PTPN11 | Navire Pharma, Inc. (US) | 2021-03-10 | — | — | EP | disclosed |
| CN-112351780-A | Substituted heterocyclic inhibitors of PTPN11 | 纳维尔制药有限公司 | 2021-02-09 | — | — | CN | disclosed |
| EP-3463343-A1 | HETEROCYCLIC INHIBITORS OF PTPN11 | Board of Regents, University of Texas System (US) | 2019-04-10 | — | — | EP | disclosed |
| WO-2017210134-A1 | HETEROCYCLIC INHIBITORS OF PTPN11 | BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM (US) | 2017-12-07 | — | — | WO | disclosed |
| US-20170342078-A1 | HETEROCYCLIC INHIBITORS OF PTPN11 | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2017-11-30 | — | — | US | disclosed |
| WO-2012066077-A1 | 1,4 DI SUBSTITUTED PYRROLIDINE - 3 - YL -AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2012-05-24 | — | — | WO | disclosed |
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | disclosed |
| US-5723611-A | Heteroarylpiperidines | SANOFI (FR) | 1998-03-03 | — | — | US | disclosed |
| US-5595994-A | 1-Halopyrazin- and 1-halopyrimidin-4-amino-4-alkylpiperidines | SANOFI (FR) | 1997-01-21 | — | — | US | disclosed |
| US-5502063-A | 1-halopyridin-4-amino-4-alkylpiperidines | SANOFI (FR) | 1996-03-26 | — | — | US | disclosed |
| CN-1106400-A | Heteroarylpiperidines, process for their preparation and pharmaceutical compositions in which they are present | SANOFI SA (FR) | 1995-08-09 | — | — | CN | disclosed |
| EP-0647639-A1 | Heteroarylpiperidines, process for their preparation and pharmaceutical compositions containing them | SANOFI (FR) | 1995-04-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342078-A1 | HETEROCYCLIC INHIBITORS OF PTPN11 | PTPRJ, PTPN11, PTPRCAP | NPFFR1 3527/4885NPFFR2 3750/4885DPP4 1080/4885 |
| US-20230109858-A1 | HETEROCYCLIC INHIBITORS OF PTPN11 | PTPRJ, PTPN11, PTPRCAP | NPFFR1 3527/4885NPFFR2 3750/4885DPP4 1080/4885 |
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | TPMT, TSLP, THPO | NPFFR1 1122/4885NPFFR2 1410/4885DPP4 521/4885 |
| US-10954243-B2 | Substituted heterocyclic inhibitors of PTPN11 | PTPN11, PTPRJ, PTPRCAP | NPFFR1 3434/4885NPFFR2 3644/4885DPP4 962/4885 |
| US-11932643-B2 | Substituted heterocyclic inhibitors of PTPN11 | PTPN11, PTPRJ, PTPRCAP | NPFFR1 3434/4885NPFFR2 3644/4885DPP4 962/4885 |
| US-20210317122-A1 | SUBSTITUTED HETEROCYCLIC INHIBITORS OF PTPN11 | PTPN11, PTPRJ, PTPRCAP | NPFFR1 3434/4885NPFFR2 3644/4885DPP4 962/4885 |
| US-11840536-B2 | Heterocyclic inhibitors of PTPN11 | PTPRJ, PTPN11, PTPRCAP | NPFFR1 3527/4885NPFFR2 3750/4885DPP4 1080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.